Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium

American Journal of Transplantation

Volumn 13, Issue 7, 2013, Pages 1871-1879

  Ashoor, I ^a   Najafian, N ^a   Korin, Y ^b   Reed, E F ^b   Mohanakumar, T ^c   Ikle, D ^d   Heeger, P S ^e   Lin, M ^e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Rho   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alloreactive T cells; biomarker; cytokine secretion assay; ELISPOT; flow cytometry; guidelines

Indexed keywords

GAMMA INTERFERON;

ALLOIMMUNITY; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GAMMA INTERFERON ELISPOT ASSAY; HUMAN; HUMAN CELL; LABORATORY TEST; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; ORGAN DONOR; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPRODUCIBILITY; STANDARD OPERATING PROCEDURE; STANDARDIZATION; SURGICAL PATIENT; SURGICAL TECHNIQUE;

CLINICAL TRIALS AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; GRAFT SURVIVAL; HUMANS; MONITORING, IMMUNOLOGIC; ORGAN TRANSPLANTATION; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TISSUE DONORS; UNITED STATES;

EID: 84879553235     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12286     Document Type: Article

References (29)

1. Lamb KE, Lodhi S, Meier-Kriesche HU., Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462.
2. Lodhi SA, Lamb KE, Meier-Kriesche HU., Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011; 11: 1226-1235.
3. Meier-Kriesche HU, Schold JD, Kaplan B., Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies ? Am J Transplant 2004; 4: 1289-1295.
4. Meyers BF, de la Morena M, Sweet SC, et al. Primary graft dysfunction and other selected complications of lung transplantation: A single-center experience of 983 patients. J Thorac Cardiovasc Surg 2005; 129: 1421-1429.
5. Suthanthiran M, Strom TB., Renal transplantation. N Engl J Med 1994; 331: 365-376.
6. Sawitzki B, Schlickeiser S, Reinke P, Volk HD., Monitoring tolerance and rejection in organ transplant recipients. Biomarkers 2011; 16 (Suppl 1): S42-S50.
7. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH., Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: Potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 2002; 13: 252-259.
8. Poggio ED, Roddy M, Riley J, et al. Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J Heart Lung Transplant 2005; 24: 1606-1613.
9. Brook MO, Wood KJ, Jones ND., The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82: 1-9.
10. Dollinger MM, Howie SE, Plevris JN, Graham AM, Hayes PC, Harrison DJ., Intrahepatic proliferation of 'naive' and 'memory' T cells during liver allograft rejection: primary immune response within the allograft. FASEB J 1998; 12: 939-947.
11. Ibrahim S, Dawson DV, Sanfilippo F., Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation 1995; 59: 724-728.
12. Le Moine A, Goldman M, Abramowicz D., Multiple pathways to allograft rejection. Transplantation 2002; 73: 1373-1381.
13. Curtsinger JM, Lins DC, Mescher MF., CD8+ memory T cells (CD44high, Ly-6C +) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J Immunol 1998; 160: 3236-3243.
14. Mondino A, Khoruts A, Jenkins MK., The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 1996; 93: 2245-2252.
15. Pihlgren M, Dubois PM, Tomkowiak M, Sjogren T, Marvel J., Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J Exp Med 1996; 184: 2141-2151.
16. Viola A, Lanzavecchia A., T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-106.
17. Morelon E, Lefrancois N, Besson C, et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after thymoglobulin induction therapy with maintenance sirolimus vs. cyclosporine. Transpl Immunol 2010; 23: 53-58.
18. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78: 1640-1646.
19. van den Boogaardt DE, van Miert PP, de Vaal YJ, de Fijter JW, Claas FH, Roelen DL., The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 2006; 82: 844-848.
20. Augustine JJ, Siu DS, Clemente MJ, Schulak JA, Heeger PS, Hricik DE., Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971-1975.
21. Gebauer BS, Hricik DE, Atallah A, et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2: 857-866.
22. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275.
23. Andree H, Nickel P, Nasiadko C, et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006; 17: 573-580.
24. Poggio ED, Augustine JJ, Clemente M, et al. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847-852.
25. Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS., Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998; 66: 219-224.
26. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19: 1419-1429.
27. Gill DK, Huang Y, Levine GL, et al. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS ONE 2010; 5: e14330.
28. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57: 303-315.
29. Augustine JJ, Poggio ED, Heeger PS, Hricik DE., Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008; 86: 529-534.